Rational therapy of bacterial vaginosis





bacterial vaginosis, antimicrobial agents, clindamycin


Purpose of the study was to evaluate the efficiency and duration of clindamycin (Banbact®) therapeutic effect  in the treatment of bacterial vaginosis in women of reproductive age.

Materials and methods. The study included 47 patients with bacterial vaginosis aged 20–37 years. Vaginal dysbiosis was established on the basis of symptoms indicated by women themselves, results of gynecological examination that was consisting of examination, measurement of vaginal pH based on the Amsels criteria, evaluation of vaginal microbiocenosis by polymerase chain reaction. Treatment was performed with Banbact® – vaginal suppositories clindamycin 100 mg 1 day before bedtime for 6 days.

Treatment criteria were no subjective complaints, normal discharge in quantity, odor and consistency; decrease of leukocytes number in smears, secretions pH <4.5, negative amine test, absence of key cells in smears, decrease of pathogenic microflora and increase of lactoflora.

Results. On the 14th day after treatment all patients noted a significant improvement in the general condition and decrease in vaginal discharge. Clue cells were detected in only in 1 patient after treatment, accounting for 2.13% of cases. The pH of discharge in all patients was significantly decreased by the 14th day after treatment. There was a clear tendency to reduce the number of G. vaginalis, staphylococci, Mobiluncus spp., A. vaginae, Streptococcus spp. and Staphylococcus spp. and appearance of lactobacilli during treatment. Results of the study show clinical effectiveness of bacterial vaginosis therapy in 93.61% of patients, and laboratory one in 90.12%. Positive effect of therapy persisted for 1 month.

Conclusion. Results of the study showed that is clindamycin (Banbact®) is an effective and optimal agent for local therapy of bacterial vaginosis in women of reproductive age. Action spectrum of the antimicrobial and antiseptic drug allows eliminating pathogenic microflora within a short period. There is no systemic effect this drug on the body.

Author Biographies

T. G. Romanenko, P.L. Shupyk NMAPE of the MoH of Ukraine, Kyiv

MD, professor, Obstetrics and Gynecology Department No. 1

G. M. Zhaloba, P.L. Shupyk NMAPE of the MoH of Ukraine, Kyiv

PhD, associate professor, Obstetrics and Gynecology Department No. 1

О. М. Sulimenko, P.L. Shupyk NMAPE of the MoH of Ukraine, Kyiv

Postgraduate student, Obstetrics and Gynecology Department No. 1


  1. Sherrard, J., Wilson, J., Donders, G., et al. “2018 European (IUSTI/WHO) Guideline on the Management of Vaginal Discharge.” Int J STD AIDS 29.13 (2018): 1258–72. DOI: 10.1177/0956462418785451
  2. Kremets, K. “Modern concepts of bacterial vaginosis and some aspects of therapy.” News of medicine and pharmacy 411 (2012): 11–12.
  3. Bulavenko, O.V., Halych, S.R., Davydova, Y.V., et al. “Problematic issues of obstetrics, gynecology and reproductive medicine in modern conditions. Review of the XIV Congress of Obstetricians and Gynecologists.” Medical aspects of woman’s health. Special issue No. 1 (2016): 16–22.
  4. Veropotvelyan, N.P., Veropotvelyan, P.N., Puhalskaya, I.N. “Bacterial vaginosis: modern approaches to treatment.” Medical aspects of woman’s health 9–10 (2010): 68–74.
  5. Australian STI Management Guidelines. Bacterial Vaginosis. Available from: [http://sti.guidelines.org.au/sexually-transmissible-infections/infections-associated-with-sex/bacterial-vaginosis].
  6. Mayorov, M.V., Zhuchenko, S.I., Chernyak, O.L. “Topical treatment of vaginal infections.” Medical aspects of women’s health 5.110 (2017): 1–7.
  7. Mayorov, M.V., Zhuchenko, S.I., Chernyak, O.L. “Bacterial vaginosis: practical etiologies, diagnostics and treatment.” Medical aspects of women's health 2.76 (2014): 55–61.
  8. Radzinsky, V.E., Khamoshina, M.B., Shelenina, L.A., et al. “Therapy of vaginal infections: the edge of the problem (international realities and Russian experience).” Doctor Ru 7.85 (2013): 13–17.
  9. Gillet, E., et al. “Association between bacterial vaginosis and CIN: systematic review and meta-analisis.” PLoS One 7/10 (2012): e45201.
  10. Gomberg, M.A. “Bacterial vaginosis and new infections associated with it.” Russian bulletin of obstetricians-gynecologists 10.2 (2010): 32–4.
  11. Laxmi, U., Agrawal, S., Raghunandan, C., et al. “Association of bacterial vaginosis with adverse fetomaternal outcome in women with spontaneous preterm labor: a prospective cohort study.” J Matern Fetal Neonatal Med 25 (2012): 64–7.
  12. Nelson, D.B., Hanlon, A., Hassan S., et al. “Preterm labor and bacterial vaginosis-associated bacteria among urban women.” J Perinat Med 37 (2009): 130–4.
  13. Nugent, R.P., Krohn, M.A., Hillier, S.L. “Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation.” J Clin Microbiol 29 (1991): 297–301.
  14. Gue´dou, F.A., Van Damme, L., Mirembe, F., et al. “Intermediate vaginal flora is associated with HIV prevalence as strongly as bacterial vaginosis in a cross-sectional study of participants screened for a randomised controlled trial.” Sex Transm Infect 88 (2012): 545–51.
  15. Ison, C.A., Hay, P.E. “Validation of a simplified grading of gram stained vaginal smears for use in genitourinary medicine clinics.” Sex Transm Infect 78 (2002): 413–5.
  16. Workowski, K.A., Berman, S.; Centers for Disease Control and Prevention (CDC). “Sexually Transmitted Diseases Treatment Guidelines, 2010.” MMWR Recomm Rep 59.RR-12 (2010): 1–10.
  17. Pirotta, M., Fethers, K.A., Bradshaw, C.S. “Bacterial vaginosis – More questions than answers.” Aust Fam Physician 38 (2009): 394–7.
  18. Bradshaw, C.S., Tabrizi, S.N., Fairley, C.K., et al. “The association of Atopobium vaginae and Gardnerella vaginalis with bacterial vaginosis and recurrence after oral metronidazole therapy.” J Infect Dis 194 (2006): 828–36.
  19. Swidsinki, A., Mendling, W., Loening-Baucke, V., et al. “An adherent Gardnerella vaginalis biofilmpersists on the vaginal epithelium after standard therapy with metronidazole.” Am J Obstet Gynecol 198 (2008): 1–6.
  20. Polatti, F. “Bacterial Vaginosis, Atopobium vaginae and Nifuratel.” Current Clinical Pharmacology 7 (2012): 36–40.
  21. Pirogova, V.I., Veresnyuk, N.S., Shchuruk, N.V. “The efficiency of complex treatment of bacterial vaginosis.” In: Collection of Scientific works of the Association of Obstetricians and Gynecologists of Ukraine. Kyiv. Polygraph plus (2012): 315–8.
  22. Machado, D., Castro, J., Palmeira-de-Oliveira, A., et al. “Bacterial Vaginosis Biofilms: Challenges to Current Therapies and Emerging Solutions.” Front Microbiol 6 (2016): 1528. DOI: 10.3389/fmicb.2015.01528
  23. Schwebke, J.R., Marrazzo, J., Beelen, A.P., Sobel, J.D. “A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of Metronidazole Vaginal Gel 1.3% in the Treatment of Bacterial Vaginosis.” Sex Transm Dis 42 (2015): 376.
  24. Sobel, J., Peipert, J.F., McGregor, J.A., et al. “Efficacy of clindamycin vaginal ovule (3-day treatment) vs. clindamycin vaginal cream (7-day treatment) in bacterial vaginosis.” Infect Dis Obstet Gynecol 9.1 (2001): 9–15.



How to Cite

Romanenko, T. G., Zhaloba, G. M., & Sulimenko О. М. (2020). Rational therapy of bacterial vaginosis. REPRODUCTIVE ENDOCRINOLOGY, (55), 58–61. https://doi.org/10.18370/2309-4117.2020.55.58-61